Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Methods in Cell Biology|February 22, 2026
Intracardiac injection as a metastatic model in lung cancerMirari Echepare, Beñat Picabea, Cristina Viu-Idocin, et al.Methods in Cell Biology|February 22, 2026
Establishment single lung tumors through orthotopic injectionBeñat Picabea, Céline Clémenson, Mirari Echepare, et al.Translational Lung Cancer Research|December 10, 2025
Establishment and characterization of an orthotopic implanted lung cancer model to mimic human tumor structure, microenvironment, and metastatic spreadBeñat Picabea, Daniel Orive, Covadonga Rodríguez, et al.Cell Reports|March 13, 2026
Targeting the DSTYK-ULK1 axis rewires TNFR1 signaling to overcome treatment resistance in lung cancerAndrea Pasquier, Cristina Viu-Idocin, Andrea Arricibita, et al.Archivos De Bronconeumologia|July 30, 2024
Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility AssessmentDaniel Orive, Mirari Echepare, Franco Bernasconi-Bisio, et al.The Journal of Experimental Medicine|September 28, 2022
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicityKarmele Valencia, Mirari Echepare, Álvaro Teijeira, et al.Disease Models & Mechanisms|December 6, 2021
Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinomaKarmele Valencia, Cristina Sainz, Cristina Bértolo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 21, 2022
YES1 Is a Druggable Oncogenic Target in SCLCEsther Redin, Eva M Garrido-Martin, Karmele Valencia, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 13, 2024
DSTYK Inhibition Sensitizes NSCLC to Taxane-Based ChemotherapyMirari Echepare, Beñat Picabea, Andrea Arricibita, et al.Signal Transduction and Targeted Therapy|June 12, 2025
Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancerBorja Ruiz-Fernández de Córdoba, Karmele Valencia, Connor Welch, et al.Pageof 1